| |
Rescue studies are not meant to be taken lightly – logistical hurdles and communication challenges are aplenty. Despite this, Premier Research doesn’t back down. See how our unique advantages helped a sponsor recover a Phase 1 oncology trial: Learn More
Premier Research. Built for Biotech℠ 
|
|
Today’s Big NewsOct 10, 2023 |
|
Thursday, October 12, 2023 | 11am ET / 8am PT A fundamental research question continues to resonate today: How can we proactively develop countermeasures against future viral outbreaks? In this webinar, leaders in industry and academia discuss their experiences using innovative tools to study and develop therapeutics against influenza, SARS-CoV-2, dengue viruses, and more. Register now. 
|
|
| By Max Bayer Biogen's new research chief Jane Grogan is looking to bring her recent biotech chops to a Big Pharma that's recalibrating. Her appointment follows a summer marked by layoffs, restructuring and a big time acquisition. |
|
|
|
By Gabrielle Masson Novartis rolled the dice in 2020 with a $210 upfront acquisition of long-time neuroscience partner Cadent Therapeutics. But the bet seems to have come up empty, as the Swiss pharma discontinues a mid-phase major depressive disorder program. |
By Nick Paul Taylor Akero Therapeutics’ nonalcoholic steatohepatitis (NASH) candidate has flunked a key test. The failure of FGF21 analog efruxifermin to significantly reduce fibrosis in cirrhotic NASH patients sent Akero’s stock tumbling—and caused fallout that dragged a rival’s share price down, too. |
Sponsored by Trinity Life Sciences In a dynamic landscape, three emerging trends have the power to reshape the complexities of pharmaceutical commercialization. |
By Annalee Armstrong After tweaking a phase 3 clinical trial for the ischemic stroke cell therapy MultiStem with the blessing of the FDA and moving forward with an enrollment goal of 300 patients, Athersys now reports that the sample size is insufficient to achieve the primary endpoint. |
Sponsored by IQVIA Greg Lever, Director within the IQVIA Applied Data Science Center, reveals how modeling technology is being used to unlock value and enhance the experience of trial participants. |
By James Waldron Sanofi’s ambition to become “the first pharma company powered by artificial intelligence at scale” came one step closer today in a deal with California’s BioMap worth over $1 billion in biobucks. |
Sponsored by AnaptysBio AnaptysBio announces top-line data showing rapid clearance of generalized pustular psoriasis (GPP), a rare systemic skin disease |
By James Waldron Immunic Therapeutics’ decision to narrow its focus in the spring appears to be paying off, with investors reacting warmly to some early biomarker data from the biotech’s multiple sclerosis candidate. |
By Nick Paul Taylor Investors are unimpressed by Ventyx Biosciences’ bid to challenge Bristol Myers Squibb and Pfizer for the ulcerative colitis market. While the phase 2 trial hit its primary endpoint, doubts about whether the drug candidate has an edge over the rival S1P1 modulators etrasimod and Zeposia sent Ventyx’s stock down. |
By Angus Liu What doctors described as a “messy” treatment landscape in early-stage non-small cell lung cancer could get clearer thanks to a first-in-class overall survival win from Merck & Co.’s Keytruda. |
By Conor Hale ANAHEIM, California—At the MedTech Conference, an FDA official described the tasks ahead as the agency moves to increase its oversight of lab-developed tests. |
By Dave Muoio Days following a three-day strike of historic scale, the large nonprofit systems' unions say an even larger demonstration—about 78,000 workers—could kick off on Nov. 1 if the parties are unable to reach a deal. |
Fierce podcasts Don’t miss an episode |
| In this episode of "The Top Line," we delve into the uncharted territory that pharma marketers face, from harnessing AI's potential to navigating the Inflation Reduction Act. |
|
|---|
|
|
Whitepaper Accelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
Whitepaper Cell and gene therapy development has exploded, with Q4 2022 showing more FDA approvals than over the past five years combined.[1] Sponsored by: Thermo Fisher Scientific |
Whitepaper Uncover the keys to efficient bioprocessing, including how outsourcing quality management can reduce risk, save time and money, and expedite biologics development. Sponsored by: Thermo Scientific™ Production Chemicals and Services |
Webinar Embark on an in-depth journey through the pivotal Make-Test-Decide Workflow, where collaboration and data-driven decisions play a paramount role in the intricate landscape of drug discovery. Watch now to learn how cloud implementation fosters accessibility and collaboration, revolutionizing research across locations and companies. Sponsored by: Revvity Signals |
eBook Learn how to get better results from suboptimal biospecimens for NGS and protein analysis. Sponsored by: Covaris |
Whitepaper Economic and regulatory factors are making biopharma supply chains more complex in the EU. This paper explores strategies that biopharma companies can use to better manage complexity, cost, and risk. Presented by: AIM, the supply chain leader for life science entrants and midsize life science companies |
Whitepaper From Assay Development Through Large Molecule Development. Streamline your R&D workflows and gain valuable insights with our Biology Solutions Brochure. Download now to discover how to control your laboratory workflows across various assay techniques, modalities, and data types. Sponsored by: Revvity Signals |
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
| Edison Ballroom, New York City |
|
|
| |
|
